Research programme: organic boron compounds - Anacor/DNDi/Pace University/SCYNEXIS/WuXi AppTec

Drug Profile

Research programme: organic boron compounds - Anacor/DNDi/Pace University/SCYNEXIS/WuXi AppTec

Latest Information Update: 20 Oct 2016

Price : $50

At a glance

  • Originator Anacor Pharmaceuticals; Drugs for Neglected Diseases Initiative Foundation; London School of Hygiene & Tropical Medicine; Pace University; SCYNEXIS; University of Antwerp; WuXi AppTec
  • Class Organic boron compounds
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Leishmaniasis
  • No development reported Trypanosomiasis

Most Recent Events

  • 16 Jul 2016 No recent reports of development identified for preclinical development in Trypanosomiasis in USA (PO)
  • 24 Jun 2016 Anacor Pharmaceuticals has been acquired by Pfizer
  • 19 May 2016 Preclinical trials in Leishmaniasis in USA (PO) (DNDi website, October 2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top